HAVCR2 and breast cancer: Treatment with anti-Gal-9 (RG9-1) or anti-TIM-3 (RMT3-23) induced activation of CD103+ DCs and CD8+ T cells in the TME and improved antitumor efficacy when combined with paclitaxel in a breast cancer model over single agent chemotherapy [153].